智通财经APP讯，长风药业(02652)发布公告，集团自主研发的长效吸入干粉候选药物ICF001(“该产品”)已获中华人民共和国国家药品监督管理局(“国家药监局”)就间质性肺病(即特发性肺纤维化(“IPF”)及进行性肺纤维化(“PPF”))开展临床试验的临床试验默示许可。
上述许可乃继该产品于2026年3月就肺动脉高压(“PAH”)及间质性肺病相关肺高压(“PH-ILD”)取得国家药监局临床试验默示许可之后取得。该产品现已获准就涵盖肺血管疾病及进行性纤维化肺病的四项适应症开展临床研究。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.